Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Mei-yu Fang"'
Autor:
Lei Lei, Wen-xian Wang, Zong-yang Yu, Xian-bin Liang, Wei-wei Pan, Hua-fei Chen, Li-ping Wang, Yong Fang, Min Wang, Chun-wei Xu, Mei-yu Fang
Publikováno v:
Translational Oncology, Vol 13, Iss 2, Pp 329-335 (2020)
BACKGROUND: KRAS gene mutations are well known as a key driver of advanced non–small cell lung cancer (NSCLC). The impact of KRAS-mutant subtypes on the survival benefit from salvage chemotherapy is controversial. Here, we present a real-world stud
Externí odkaz:
https://doaj.org/article/8735d400c9f345c390e3a3ece24e3adf
Autor:
Lei Lei, Wen‐xian Wang, You‐cai Zhu, Jin‐luan Li, Yong Fang, Hong Wang, Wu Zhuang, Yin‐bin Zhang, Li‐ping Wang, Mei‐yu Fang, Chun‐wei Xu, Xiao‐jia Wang, Tang‐feng Lv, Yong Song
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 12-18 (2020)
Abstract The response to icotinib in advanced non‐small cell lung cancers (NSCLC) with EGFR uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential resistance mechanism of icotinib in Chinese EGFRum NSCLC patients. Betwee
Externí odkaz:
https://doaj.org/article/35dceeb41cdd4f86a8452ce1072e9fca
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Salivary duct carcinoma (SDC), an aggressive and rare malignancy with poor prognosis, is mostly associated with the overexpression of the androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2). However, limited data ar
Externí odkaz:
https://doaj.org/article/0a64f7e267184e5d8f2082b37c67e648
Autor:
Chun-wei Xu, Lei Lei, Wen-xian Wang, Li Lin, You-cai Zhu, Hong Wang, Li-yun Miao, Li-ping Wang, Wu Zhuang, Mei-yu Fang, Tang-feng Lv, Yong Song
Publikováno v:
Translational Oncology, Vol 13, Iss 9, Pp 100791- (2020)
Epidermal growth factor receptor (EGFR) exon 19 deletion (E19del) is the most common activating mutation in advanced non–small cell lung cancer (NSCLC) and associates with the sensitivity of EGFR tyrosine kinase inhibitors (TKIs) treatment. However
Externí odkaz:
https://doaj.org/article/9fe5da973a6c44378c93ffab8bef4d4b
Autor:
Dong Chen, Xing-liang Li, Biao Wu, Xiao-bin Zheng, Wen-xian Wang, Hua-fei Chen, Yi-yu Dong, Chun-wei Xu, Mei-yu Fang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Introduction: Oncogenic mutations in the epidermal growth factor receptor (EGFR) occur frequently in patients with lung cancer. These mutations may serve as critical predictive biomarkers in patients with non-small cell lung cancer (NSCLC). Among the
Externí odkaz:
https://doaj.org/article/fc4d846b0f4b4182aeba9c4455ceadd0
Autor:
Xiao-Feng Li, Chunwei Xu, You-cai Zhu, Huafei Chen, Huang Lichao, Wenxian Wang, Gang Lan, Kai-qi Du, Mei-yu Fang, Zhan-qiang Zhai, Lei Lei
Publikováno v:
Lung Cancer. 142:59-62
Objectives Transforming anaplastic lymphoma kinase (ALK) gene rearrangements are well known as a unique subset of non-small cell lung cancer (NSCLC) with mutations other than EGFR. Currently, crizotinib is the standard first-line treatment for ALK-po
Autor:
Lei Lei, Wen-Xian Wang, Hong Wang, Wu Zhuang, Mei‐yu Fang, Yong Fang, Yinbin Zhang, You-cai Zhu, Liping Wang, Chunwei Xu, Xingxiang Pu
Publikováno v:
Translational Cancer Research
Background BRAF mutation plays a rare but aggressive oncogenic role in non-small cell lung cancer (NSCLC) patients. The controversy of first-line chemotherapy in patients with different BRAF mutations exists. Here, we identified 41 stage IIIB/IV NSCL
Autor:
Yong Fang, Yinbin Zhang, Chunwei Xu, You-cai Zhu, Tangfeng Lv, Jinluan Li, Liping Wang, Lei Lei, Wu Zhuang, Xiao‐jia Wang, Mei‐yu Fang, Yong Song, Hong Wang, Wenxian Wang
Publikováno v:
Cancer Science
The incidence of epidermal growth factor receptor uncommon mutation (EGFRum) is relatively low and patients harboring EGFRum are resistant to the first‐generation tyrosine kinase inhibitors (TKI). However, the mechanism of primary resistance remain
ROS1-rearranged non-small cell lung cancer (NSCLC) is a subset of NSCLC patients with unique malignant behavior and clinical course. Crizotinib, a multi-targeted ALK/ROS1/MET tyrosine kinase inhibitor (TKI), has promising significant activity in NSCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6b868cdef9510cb814c7c40fc1c40e4
https://doi.org/10.21203/rs.3.rs-989538/v1
https://doi.org/10.21203/rs.3.rs-989538/v1
Autor:
Chun-Wei, Xu, Wen-Xian, Wang, Dong, Wang, Qi-Ming, Wang, Xing-Xiang, Pu, You-Cai, Zhu, Jian-Hui, Huang, Zong-Yang, Yu, Zhao-Lei, Cui, Xiao-Hui, Chen, Jin-Luan, Li, Yong, Fang, Hong, Wang, Wu, Zhuang, Shi-Jie, Lan, Xin, Cai, Yin-Bin, Zhang, Wen-Bin, Gao, Li-Ping, Wang, Ke-Lin, She, Chuang-Zhou, Rao, Yue-Fen, Zhou, Mei-Yu, Fang, Li-Yun, Miao, Lei, Lei, Tang-Feng, Lv, Yong, Song
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Chemotherapy is the major choice for advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor exon 20 insertion (EGFR ex20ins). The efficacy of pemetrexed-based with other chemotherapy regimens and EGFR e